BETA-BLOCKERS - DRUG-INTERACTIONS OF CLINICAL-SIGNIFICANCE

被引:12
作者
BLAUFARB, I [1 ]
PFEIFER, TM [1 ]
FRISHMAN, WH [1 ]
机构
[1] YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV CARDIOL,BRONX,NY 10461
关键词
D O I
10.2165/00002018-199513060-00005
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The clinician prescribing beta-blockers for his or her patients is faced with an often difficult situation. There are many beta-blockers, each with its own pharmacological profile. Patients are often taking multiple medications, thus increasing the risk of both anticipated and unexpected drug interactions. Reports of drug interactions are frequently anecdotal. The prescriber may not be aware of the patient's other medications or lifestyle habits. Pharmacokinetic and pharmacodynamic drug interactions involving beta-blockers are documented in the literature, but these studies often examine small numbers of patients. For these reasons, it is difficult for the practitioner to distill guidelines for the administration of beta-blockers in conjunction with other medication. In general, beta-blockers are well tolerated, and symptomatic drug interactions are relatively infrequent. It is incumbent upon the clinical practitioner to have knowledge of his or her patient's drug profile and to be aware of the various drug interactions as well as each patient's unique pathophysiological profile when prescribing any medication, including beta-blockers. beta-Blockers may interact with a large number of commonly prescribed drugs, including antihypertensive and antianginal drugs, inotropic agents, antiarrhythmics, NSAIDs, psychotropic drugs, anti-ulcer medications, anaesthetics, HMG-CoA reductase inhibitors, warfarin, oral hypoglycaemics and rifampicin (rifampin).
引用
收藏
页码:359 / 370
页数:12
相关论文
共 111 条
[1]  
Beeley L., Drug interactions and beta-blockers, BMJ, 289, (1984)
[2]  
McDevitt D.G, Drug interactions involving beta-adrenoreceptor blocking drugs, Cardiovasc Respir Dis Ther, 1, pp. 21-41, (1980)
[3]  
Wood A.J.J., Feely J., Pharmacokinetic drug interactions with propranolol, Clin Pharmacokinet, 8, (1983)
[4]  
Heagerty A.M., Donovan M.A., Castleden C.M., Et al., Influence of cimetidine on pharmacokinetic s of propranolol, BMJ, 282, (1981)
[5]  
Kirch W., Kohler H., Spahn H., Et al., Interaction of cimetidine with metoprolol, propranolol or atenolol, Lancet, 2, (1981)
[6]  
Kater R.M.H., Roggin G., Tobboon F., Et al., Increased rate of clearance of drugs from the circulation of alcoholics, Am J Med Sci, 258, (1969)
[7]  
Jusko W.J., Role of tobacco smoking in pharmacokinetics, J Pharmacokinet Biopharm, 6, pp. 7-39, (1978)
[8]  
Deanfield J., Wright C., Krikler S., Et al., Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine, N Engl J Med, 310, 15, (1984)
[9]  
Walle T., Walle U.K., Cowart T.D., Et al., Selective induction of propranolol metabolism by smoking: additional effects on renal clearance of metabolites, J Pharmacol Exp Ther, 241, (1987)
[10]  
Sotaniemi E.A., Anttila M., Rautio A., Et al., Propranolol and sotalol metabolism after a drinking party, Clin Pharmacol Ther, 29, 6, (1981)